Hypertension and risk of prostate cancer: a systematic review and meta-analysis

被引:0
作者
Zhen Liang
Bo Xie
Jiangfeng Li
Xiao Wang
Song Wang
Shuai Meng
Alin Ji
Yi Zhu
Xin Xu
Xiangyi Zheng
Liping Xie
机构
[1] First Affiliated Hospital,Department of Urology
[2] School of Medicine,Department of Urology
[3] Zhejiang University,Department of Urology
[4] Tongde Hospital of Zhejiang Province,undefined
[5] Zhejiang Provincial People’s Hospital,undefined
来源
Scientific Reports | / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The previously reported association between hypertension and prostate cancer risk was controversial. We performed this systematic review and meta-analysis of all available studies to summarize evidence on this association. Studies were identified by searching PubMed, Web of Science and Chinese National Knowledge Infrastructure (CNKI) databases through January 2016. Pooled relative risks (RRs) with their corresponding 95% confidence intervals (CIs) were calculated using a random-effects model. A total of 21 published studies were included in this meta-analysis. A significant increase in the risk of prostate cancer (RR 1.08, 95% CI 1.02–1.15, P = 0.014) was observed among individuals with hypertension. There was statistically significant heterogeneity among included studies (P < 0.001 for heterogeneity, I2 = 72.1%). No obvious evidence of significant publication bias was detected by either Begg’s test (P = 0.174) or Egger’s test (P = 0.277). In conclusion, this meta-analysis indicates that hypertension may be associated with an increased risk of prostate cancer. Considering the substantial heterogeneity and residual confounding among included studies, further large-scale, well-designed prospective cohorts, as well as mechanistic studies, are urgently needed to confirm our preliminary findings.
引用
收藏
相关论文
共 50 条
[21]   Folate intake and the risk of prostate cancer: a systematic review and meta-analysis [J].
Tio, M. ;
Andrici, J. ;
Cox, M. R. ;
Eslick, G. D. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2014, 17 (03) :213-219
[22]   Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis [J].
Zexing Wang ;
Jing Xu ;
Weiwei Nie ;
Guichun Huang ;
Jinhai Tang ;
Xiaoxiang Guan .
European Journal of Clinical Pharmacology, 2014, 70 :225-231
[23]   Hyperuricemia and The Risk of Hypertension: A Systematic Review and Meta-Analysis [J].
Untari, P. U. ;
Daindes, T. .
JOURNAL OF HYPERTENSION, 2023, 41 (SUPPL 2)
[24]   Hypertension and risk of cholangiocarcinoma: a systematic review and meta-analysis [J].
Xiong, Jianping ;
Xu, Weiyu ;
Huang, Hanchun ;
Bian, Jin ;
Lin, Jianzhen ;
Long, Junyu ;
Bai, Yi ;
Xu, Yiyao ;
Chi, Tianyi ;
Lu, Xin ;
Zhao, Haitao .
TRANSLATIONAL CANCER RESEARCH, 2018, 7 (03) :543-551
[25]   Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis [J].
Wei-Xiang Qi ;
Zan Shen ;
Li-Na Tang ;
Yang Yao .
Clinical Drug Investigation, 2014, 34 :231-240
[26]   Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis [J].
Applegate, Catherine C. ;
Rowles, Joe L., III ;
Ranard, Katherine M. ;
Jeon, Sookyoung ;
Erdman, John W., Jr. .
NUTRIENTS, 2018, 10 (01)
[27]   Vasectomy and risk of prostate cancer: a systematic review and meta-analysis of cohort studies [J].
Liu, L. H. ;
Kang, R. ;
He, J. ;
Zhao, S. K. ;
Li, F. T. ;
Wan, S. P. ;
Zhao, Z. G. .
ANDROLOGY, 2015, 3 (04) :643-649
[28]   Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis [J].
Benke, I. N. ;
Leitzmann, M. F. ;
Behrens, G. ;
Schmid, D. .
ANNALS OF ONCOLOGY, 2018, 29 (05) :1154-1179
[29]   INFLAMMATORY BOWEL DISEASE AND RISK OF PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS [J].
Wadhwa, Vaibhav ;
Selema, Kristen ;
Rodriguez, Katia ;
Shen, Bo ;
Charles, Roger .
GASTROENTEROLOGY, 2018, 154 (06) :S409-S410
[30]   Risk of prostate cancer in men with HIV/AIDS: a systematic review and meta-analysis [J].
Sun, Dianqin ;
Cao, Maomao ;
Li, He ;
Ren, Jiansong ;
Shi, Jufang ;
Li, Ni ;
Chen, Wanqing .
PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (01) :24-34